Niagen Bioscience, Inc.
NAGE
$10.10
$0.373.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,129.07% | 6,197.37% | 295.83% | 99.32% | 74.13% |
| Total Depreciation and Amortization | -9.72% | -4.02% | -18.30% | -16.67% | -50.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -104.61% | -478.49% | -43.72% | -31.38% | -24.60% |
| Change in Net Operating Assets | 516.95% | 660.42% | 219.19% | -156.49% | -124.32% |
| Cash from Operations | 2,572.20% | 1,222.50% | 782.58% | -108.05% | -89.43% |
| Capital Expenditure | 21.95% | -228.57% | -57.69% | -20.00% | 54.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 21.95% | -228.57% | 19.23% | -140.00% | 54.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -100.00% | -33.33% | 80.00% | -200.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 45.45% | 45.33% | -- | -- | -- |
| Cash from Financing | 22,278.57% | 5,031.58% | 34,733.33% | 6,060.00% | -1,300.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,465.00% | 2,121.38% | 1,129.70% | -90.20% | -91.11% |